866-997-4948(US-Canada Toll Free)

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2019

Published By :

GlobalData

Published Date : May 2019

Category :

Medical Equipments

No. of Pages : 168 Pages

Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, Metered Dose Inhaler Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Metered Dose Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Metered Dose Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Metered Dose Inhaler Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Metered Dose Inhaler Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry.

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Metered Dose Inhaler Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Metered Dose Inhaler Devices Overview
3 Products under Development
3.1 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
3.2 Metered Dose Inhaler Devices - Pipeline Products by Territory
3.3 Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
3.4 Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
3.5 Metered Dose Inhaler Devices - Ongoing Clinical Trials
4 Metered Dose Inhaler Devices - Pipeline Products under Development by Companies
4.1 Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
4.2 Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
5 Metered Dose Inhaler Devices Companies and Product Overview
5.1 Adamis Pharmaceuticals Corp Company Overview
5.2 Aerophase Inc Company Overview
5.3 AstraZeneca Plc Company Overview
5.4 Circassia Pharmaceuticals Plc Company Overview
5.5 Globe Medical Tech Inc (Inactive) Company Overview
5.6 Lab Automate Technologies Inc Company Overview
5.7 Lupin Pharmaceuticals Inc Company Overview
5.8 Medicom Innovation Partner a/s Company Overview
5.9 Min USA LLC Company Overview
5.10 Pearl Therapeutics Inc Company Overview
5.11 Reciprocal Labs Corp Company Overview
5.12 Rensselaer Polytechnic Institute Company Overview
5.13 Vectura Group Plc Company Overview
5.14 Verona Pharma Plc Company Overview
6 Metered Dose Inhaler Devices- Recent Developments
6.1 Apr 30, 2019: Merck announces first-quarter 2019 financial results
6.2 Apr 24, 2019: Novartis starts 2019 with strong sales and double digit core operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
6.3 Apr 17, 2019: Financial year 2018: Boehringer Ingelheim grows and invests
6.4 Apr 12, 2019: Cipla launches Niveoli, Indias first extra-fine ICS-LABA combination HFA inhaler
6.5 Apr 09, 2019: Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
6.6 Apr 02, 2019: Alcon announces Timothy Stonesifer as Chief Financial Officer
6.7 Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility
6.8 Apr 01, 2019: Vectura Group names Kevin Matthews to its board of directors
6.9 Mar 26, 2019: Vectura Group 2018 preliminary results
6.10 Mar 22, 2019: Sosei Heptares announces that Ultibro Breezhaler and Seebri Breezhaler launched in China for the treatment of COPD
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer

1.1 List of Tables
Table 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Table 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Table 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Table 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials
Table 6: Metered Dose Inhaler Devices Companies - Pipeline Products by Stage of Development
Table 7: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Table 8: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Beclomethasone MDI - Product Status
Table 10: Beclomethasone MDI - Product Description
Table 11: Aerophase Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Metered Dose Inhaler - Product Status
Table 13: Metered Dose Inhaler - Product Description
Table 14: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Bevespi Aerosphere Inhalation Aerosol - Product Status
Table 16: Bevespi Aerosphere Inhalation Aerosol - Product Description
Table 17: AstraZeneca Plc - Ongoing Clinical Trials Overview
Table 18: Bevespi Aerosphere Inhalation Aerosol - A Phase I, Single-dose, Gamma Scintigraphy Study to Assess the Pulmonary Deposition of Technetium-99m Radiolabelled Budesonide, Glycopyrronium and Formoterol Fumarate MDI in Patients with Moderate to Severe/Very Severe COPD
Table 19: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 20: Fliveo - Product Status
Table 21: Fliveo - Product Description
Table 22: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Status
Table 23: Fluticasone propionate/Salmeterol xinafoate pMDI - Product Description
Table 24: Circassia Pharmaceuticals Plc - Ongoing Clinical Trials Overview
Table 25: Fluticasone propionate/Salmeterol xinafoate pMDI - A Phase III Registration Study of Seretide Substitute (PSX2005)
Table 26: Globe Medical Tech Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 27: Inhaler - Product Status
Table 28: Inhaler - Product Description
Table 29: Lab Automate Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Ultrasonic Metered Dose Inhaler - Product Status
Table 31: Ultrasonic Metered Dose Inhaler - Product Description
Table 32: Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Albuterol MDI - Product Status
Table 34: Albuterol MDI - Product Description
Table 35: Medicom Innovation Partner a/s Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Asmair - Product Status
Table 37: Asmair - Product Description
Table 38: Min USA LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 39: Envi - Product Status
Table 40: Envi - Product Description
Table 41: Pearl Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 42: PT001 - Product Status
Table 43: PT001 - Product Description
Table 44: PT010 - Product Status
Table 45: PT010 - Product Description
Table 46: Pearl Therapeutics Inc - Ongoing Clinical Trials Overview
Table 47: PT010 - A Randomized, Double-blind, Multi-center, Parallel-group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects with Moderate to Very Severe COPD (Ethos)
Table 48: Reciprocal Labs Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 49: Connected Metered Dose Inhaler - Product Status
Table 50: Connected Metered Dose Inhaler - Product Description
Table 51: Rensselaer Polytechnic Institute Pipeline Products & Ongoing Clinical Trials Overview
Table 52: Bloom Inhaler - Product Status
Table 53: Bloom Inhaler - Product Description
Table 54: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 55: Flutiform pMDI - Product Status
Table 56: Flutiform pMDI - Product Description
Table 57: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 58: RPL554 - Metered Dose Inhaler - Product Status
Table 59: RPL554 - Metered Dose Inhaler - Product Description
Table 60: Glossary

1.2 List of Figures
Figure 1: Metered Dose Inhaler Devices - Pipeline Products by Stage of Development
Figure 2: Metered Dose Inhaler Devices - Pipeline Products by Territory
Figure 3: Metered Dose Inhaler Devices - Pipeline Products by Regulatory Path
Figure 4: Metered Dose Inhaler Devices - Pipeline Products by Estimated Approval Date
Figure 5: Metered Dose Inhaler Devices - Ongoing Clinical Trials

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *